Barclays
DRMA icon

Barclays’s Dermata Therapeutics DRMA Stock Holding History

Barclays’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348 Buy
+270
New +$340 ﹤0.01% 5051
2026
Q1 		– Sell
-2,402
Closed -$5.57K – 5141
2025
Q4 		$5.57K Buy
+2,402
New +$7.85K ﹤0.01% 4979

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AA
Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays's DRMA Position: Q2 2026 in Review

Barclays opened a new position in Dermata Therapeutics (DRMA) in Q2 2026: 270 shares worth $348. The stake represents ﹤0.01% of the portfolio and ranks #5051 among its holdings. This is a return to the name: Barclays previously reported a position in DRMA as recently as Q4 2025.

Barclays first reported a position in DRMA in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.57K in Q4 2025. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

  • Barclays held 270 shares of Dermata Therapeutics worth $348 as of Q2 2026.
  • Dermata Therapeutics was a new Barclays position in Q2 2026.
  • Dermata Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5051 holding.
  • Barclays first reported a position in Dermata Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Barclays's Dermata Therapeutics position peaked at $5.57K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.